Leishmaniasis Vaccines

11/01/2008 - "Given the urgent need to identify a safe and effective Leishmania vaccine to help prevent the two million new cases of human leishmaniasis worldwide each year, all reasonable efforts to achieve this goal should be made. "
01/01/1996 - "The objective was to determine the ecology of natural reservoir hosts of leishmaniasis for possible future field trials of leishmania vaccine. "
04/16/2023 - "Here, we revisited molecular targets associated with the selection of live-attenuated vaccinal strains, discussing their function, their limiting factors and the ideal candidate for the next generation of genetically engineered live-attenuated Leishmania vaccines to control leishmaniasis."
11/01/2021 - "Since there are several forms of leishmaniasis, a pan-Leishmania vaccine without geographical restrictions is needed. "
10/29/2020 - "Overall our immunogenicity data suggests that to design a potentially safe vector-based pan-Leishmania vaccine, without geographic restrictions and against all forms of leishmaniasis is an achievable goal. "

09/01/2021 - "Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice."
01/01/2021 - "Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis."
07/01/2015 - "Development of Leishmania vaccines in the era of visceral leishmaniasis elimination."
02/27/2013 - "These results provide a possible rationale for the scarcity of visceral leishmaniasis in Sri Lanka and could guide leishmaniasis vaccine development efforts."
01/01/2022 - "LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis."

01/01/2023 - "These findings indicate that αGalCer improves protection against cutaneous leishmaniasis, supporting evidence for its potential use as adjuvant in Leishmania-vaccines."
06/01/1997 - "Emanuela Handman here discusses the current studies and the future prospects for a Leishmania vaccine with a focus on cutaneous leishmaniasis. "
06/01/1997 - "In the search for a leishmaniasis vaccine, extensive studies of cutaneous leishmaniasis have been carried out. "
02/20/2016 - "TLR2 plays a role in parasite recognition and activation of immune responses during cutaneous leishmaniasis infection, suggesting that TLR2 could be targeted by adjuvants for use in Leishmania vaccines. "
09/01/2007 - "Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World."

06/01/2009 - "Remarkably, the efficacy of anti-Leishmania vaccines has never been fully evaluated under experimental conditions following natural vector transmission by infected sand fly bite. "
05/01/2009 - "Their inclusion in an anti-Leishmania vaccine would exploit anti-saliva immunity following an infective sand fly bite and set the stage for a protective anti-Leishmania immune response."
11/15/2012 - "Numerous experimental Leishmania vaccines have been developed to prevent the visceral and cutaneous forms of Leishmaniasis, which occur after exposure to the bite of an infected sand fly, yet only one is under evaluation in humans. "
01/01/2016 - "For example, the fact that individuals living in endemic areas are exposed to sand fly bites and will mount an immune response to salivary proteins should be considered in pre-clinical and clinical evaluation of leishmaniasis vaccines. "

10/01/2004 - "However, the development of a Leishmania vaccine effective in preventing these chronic diseases has proven to be a challenge. "